Kalkine has a fully transformed New Avatar.

blue-chip

Stay Invested in This NASDAQ-Listed IT Major - CGNX

Oct 18, 2021 | Team Kalkine
Stay Invested in This NASDAQ-Listed IT Major - CGNX

Cognex Corporation

CGNX Details

Cognex Corporation (NASDAQ: CGNX) is a global manufacturer and distributor of machine vision technologies that enable businesses to automate their manufacturing and distribution processes. It also provides maintenance and support, consultancy, and training. CGNX's key products include machine vision systems and sensors, vision software, and image-based barcode scanners (ID devices).

Latest News:

  • Payment of Dividend: On August 05, 2021, CGNX declared a quarterly dividend of USD 0.06 per common share, paid on September 03, 2021, to shareholders of record on August 20, 2021.

H1FY21 Results:

  • Significant Growth in Revenue: The company reported a YoY surge of 51.10% in revenues to USD 508.19 million during H1FY21 (ended July 04, 2021) from USD 336.33 million during H1FY20 (ended June 28, 2021), attributable to broad-based recovery from the COVID-19 pandemic.
  • Surge in Profitability: CGNX reported a sharp uptick in net income to USD 147.45 million during H1FY21 vs. USD 19.34 million in H1FY20.
  • Cash and Debt Position: As of July 04, 2021, the company had cash and cash equivalents (including marketable securities) of USD 407.78 million and no outstanding debt.

Key Risks:

  • Customer Concentration Risk: CGNX's top two customers accounted for the majority of its FY20 revenue. As a result, the loss of any of these key customers could hurt the company's financials.
  • Competition Risk: CGNX operates in a highly competitive machine vision industry and faces aggressive price competition from its significant players, which could cause pricing pressure for the company. Should this trend continue, it could harm the financials of the company.

Outlook:

  • Revenue Estimate: As of Q2FY21, CGNX expects its Q3FY21 revenues to range between USD 275 – 295 million, along with a gross margin of low to mid 70% range.
  • Operating Expenses: Operating expenses for the next quarter are also expected to grow in mid-single digits on a sequential basis due to increasing sales activities and investments in engineering and sales, support for large deployments of Cognex technologies, and planned product launches.

Valuation Methodology: Price/Earnings Multiple Based Relative Valuation

(Analysis by Kalkine Group)

  • % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

CGNX Daily Technical Chart (Source: REFINITIV)

Stock Recommendation:

CGNX's stock price rose 5.42% in the past three months and is currently leaning towards the mid-band of the 52-week range of USD 62.55 to USD 101.82. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 57.56. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 96.14.

Considering the company's growth prospects, solid margins, current valuation, and associated risks, we recommend a "Hold" rating on the stock at the current price of USD 85.71, up 1.54% as of October 18, 2021, 12:05 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

*All forecasted figures and industry information have been taken from REFINITIV.  


Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.


Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.